Raising of funds by way of issue of equity shares of the Company on right issue basis

Corporate Actions View source PDF Explain this filing

KILITCH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹222.50

prior close

₹222.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%-0.3% vs market

Pharmaceuticals peers, median of 150sector-0.1%-0.4% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.1

15m

+0.1

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-0.2-0.3-0.1-0.4

Next day

-1.1-0.1-1.0+0.2-1.3

-3.3+0.3-3.7+0.4-3.8

-3.4-0.2-3.2-0.1-3.3

-5.2-0.3-4.9-0.3-4.8

-5.6+0.2-5.8-0.1-5.5

+4.3+0.1+4.3-0.6+4.9

15d

-2.1+1.2-3.3-0.1-2.1

-0.2-2.2+2.0-2.1+1.9

-21.3-3.0-18.3-4.6-16.7

-22.6-2.9-19.7-3.2-19.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kilitch Drugs (India) Limited announced that its Board of Directors, at a meeting held on July 2, 2025, approved raising funds up to Rs. 50 crores through a Rights Issue of equity shares with a face value of Rs. 10 each. The proceeds will be used to fund capital expenditure for a Greenfield Project in Pen, Maharashtra, as well as for general corporate purposes and right issue-related expenses. The record date for identifying eligible shareholders will be notified separately, and detailed terms will be included in the Letter of Offer to be sent to eligible shareholders. The company has also sought in-principal approval for the rights issue under applicable SEBI regulations.

Likely market impact

The rights issue will dilute existing shareholders' stakes unless they fully participate. The fresh capital injection signals growth plans via the new Greenfield manufacturing facility, which could support long-term business expansion if the project delivers expected returns.